^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
CLL/SLL with del(17p)/TP53 mutation: Relapsed/refractory therapy...Preferred regimens…Venetoclax
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Chronic Lymphocytic Leukemia)
New
Excerpt:
Venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor.